Soliqua 100/33 bests insulin glargine in earlier blood sugar control

In certain adults with type 2 diabetes, French pharma major Sanofi's (Euronext: SAN) Soliqua100/33 (insulin glargine and lixisenatide injection, 100 Units/mL & 33 mcg/mL) provided blood sugar control earlier and in more adults than those treated with insulin glargine 100 Units/mL alone, according to a new post-hoc analysis of key late-stage clinical trials.

"Reaching an HbA1c target quickly can have a benefit for adults with type 2 diabetes," said Dr Juan Frias, president and principal investigator of the National Research Institute in Los Angeles, California, USA, adding: "Early, effective glycemic control can lead to better outcomes, both clinically and in terms of the overall cost of care."

The analysis was presented today at the European Association for the Study of Diabetes (EASD) 53rd Annual Meeting, in Lisbon, Portugal.